INSIGHT-Doctors grapple with best use of potent new cancer drugs
* Race is on for immunotherapy combinations in lung cancer
* Merck set to dominate in patients with high PD-L1 protein
* Seventy percent of first-line market still up for grabs
* At stake the health of millions, outlook for drugs giants
By Ben Hirschler
COPENHAGEN, Oct 10 (Reuters) - Evelyn O'Flynn still has lung cancer. But after going straight on to a new immune system-boosting drug more than a year ago, rather than traditional hard-to-tolerate chemotherapy, she is feeling great.
"It's like a miracle," said the 72-year-old ex-smoker, who is about to become a great-grandmother.
As a patient being treated with Merck & Co's immunotherapy drug Keytruda, O'Flynn is one of the lucky ones.
Data presented at the European Society for Medical Oncology (ESMO) congress suggest her early treatment with immunotherapy, as part of a clinical trial in Britain, will become standard for a growing number of patients. Continued...